Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy

ConclusionRAS/BRAF mutations did not affect the response to NAC. However, the RFS was likely to be poor for those in the MT group who did not achieve favorable pathological response. In contrast, the RFS was favorable in the WT group regardless of the pathological response.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research